Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting

A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is presented. 12 neurologists from different medical institutions in Russia and Belarus took part in the work of the Council. In the conclusions of the Council, special attention was paid to two new Russian original drugs, modifying the course of MS. The place of these drugs in the healthcare system of these countries was determined. Sampeginterferon beta-1a itself is an effective and safe drug of first choice (first-line treatment) for relapsing remitting MS. Divozilimab is a highly effective and safe second-line treatment indicated for rapidly progressive and highly active MS, even when substituted for a firstor second-line treatment in relapsing remitting and secondary progressive (with exacerbations) MS. The experts emphasized how promising the use of these drugs is in the complex treatment of MS.

1. Kulikov AYu, Tishchenko DG. Economic burden of multiple sclerosis in the Republic of Belarus. Farmakoekonomika: teoriya i praktika. 2015;3(2):96-101 (In Russ.).

2. Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoye rukovodstvo [Multiple sclerosis. Scientific and practical guide]: In 2 volumes. Moscow: ROOI “Human Health”; 2020. Vol. 1. 608 p. ISBN 978-5-6044140-2-6; Vol. 2. 566 p. ISBN 978-5-6044140-5-7 (In Russ.)].

3. Smirnov VS, Galinovskaya NV. Clinical characteristics of patients with multiple sclerosis according to the registry of the Gomel region. Mediko-biologicheskie problemy zhiznedeyatel'nosti = Medical and Biological Problems of Life Activity. 2022;(1):124-34 (In Russ.).

4. Wiendl H, Gold R, Berger T, et al; 'Multiple Sclerosis Therapy Consensus Group' (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648

5. Boyko AN, Bakhtiyarova KZ, Dudin VA, et al. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10-2):100-9. doi: 10.17116/jnevro2019119102100 (In Russ.)].

6. Boyko AN, Boyko OV, Bakhtiyarova KZ, et al. Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162 (In Russ.)].

7. Boyko AN, Bakhtiyarova KZ, Boyko OV, et al. Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(2):52-9. doi: 10.17116/jnevro202312302152 (In Russ.).

8. Prosperini L, Mancinelli CR, Solaro CM, et al. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics. 2020 Jul;17(3):994-1004. doi: 10.1007/s13311-020-00847-0

9. Boyko OV, Boyko AN, Yakovlev PA, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10-2):87-95. doi: 10.17116/jnevro201911910287 (In Russ.).

10. Boyko AN, Alifirova VM, Lukashevich IG, et al. Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(4):37-47. doi: 10.17116/jnevro202312304137 (In Russ.).